CSO and General Manager - Nuclea Diagnostics

Since 1997, Walter Carney have been the Head of the Oncogene Science organization, which functions as a center of Oncology Excellence for Siemens Dx. Oncogene Science develops, manufactures and distributes oncology biomarker products. I have published over 250 articles and abstracts, have been awarded over 25 patents and have numerous pending patent applications. In addition to being the inventor of the circulating HER-2/neu protein test, he has been a leader in integrating the FDA cleared test into the clinical management of women with HER-2 Positive Breast Cancer. Since 1997, Walter Carney have been the Head of the Oncogene Science organization, which functions as a center of Oncology Excellence for Siemens Dx. Oncogene Science develops, manufactures and distributes oncology biomarker products. He has published over 250 articles and abstracts, have been awarded over 25 patents and have numerous pending patent applications. In addition to being the inventor of the circulating HER-2/neu protein test, he has been a leader in integrating the FDA cleared test into the clinical management of women with HER-2 Positive Breast Cancer.